ForPatients
by Roche

Hemophilia A

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN2)

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Trial Status	Trial Runs In	Trial Identifier
Completed	10 Countries	NCT02795767 2016-000073-21, HAVEN2 BH29992

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.

Hoffmann-La Roche Sponsor	**Phase 3** Phase

NCT02795767 2016-000073-21, HAVEN2 BH29992
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	<= 17 Years	No

© 2022 F. Hoffmann-La Roche Ltd